U.S. News Room
Thu May 28 00:00:00 GMT-05:00 2026
NEW
Daiichi Sankyo Showcases Progress Across Industry-Leading Oncology Portfolio with Latest Research Updates at ASCO
Download
Fri May 22 00:00:00 GMT-05:00 2026
NEW
Datroway Approved in the US as First TROP2 Directed Antibody Drug Conjugate for First-Line Treatment of Patients with Metastatic Triple Negative Breast Cancer Who Are Not PD-1/PD-L1 Inhibitor Candidates
Download
Fri May 15 00:00:00 GMT-05:00 2026
NEW
Enhertu Approved in the US for Two New Indications for Patients with HER2 Positive Early Breast Cancer
Download
Mon May 11 00:00:00 GMT-05:00 2026
NEW
Daiichi Sankyo Unveils New Five-Year Business Plan Focused on Oncology Leadership and Innovation
Download
Mon Apr 13 00:00:00 GMT-05:00 2026
Ifinatamab Deruxtecan Granted Priority Review in the US for Adult Patients with Previously Treated Extensive-Stage Small Cell Lung Cancer who Experienced Disease Progression on or After Platinum-Based Chemotherapy
Download
Mon Mar 09 00:00:00 GMT-05:00 2026
Patent Dispute Between Daiichi Sankyo and Seagen has Concluded
Mon Mar 09 00:00:00 GMT-05:00 2026
ENHERTU Granted Priority Review in the US as Post-Neoadjuvant Treatment for Patients with HER2 Positive Early Breast Cancer
Download
Thu Feb 19 00:00:00 GMT-05:00 2026
Daiichi Sankyo Appoints John Tsai, MD as Global Head of R&D
Download
Wed Feb 04 00:00:00 GMT-05:00 2026
DS3790 Enters Clinical Development as First DXd ADC in Hematology from Industry-Leading ADC Portfolio of Daiichi Sankyo
Download
Tue Feb 03 00:00:00 GMT-05:00 2026
DATROWAY Granted Priority Review in the US as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy
Download